CIRM Funded Clinical Trials

Progenitor Cells Secreting GDNF for the Treatment of ALS

CIRM Grant:
CLIN2-09284 (Closed)
Award Value:
Trial Stage:
Phase 1/2
Trial Status:
Targeted Enrollment:
18 ID:


ALS is a devastating neurodegenerative disease with no cure that specifically affect a patient’s motor neurons in the brain. A team at Cedars-Sinai is transplanting millions of genetically engineered stem cells into patients with ALS. When transplanted into the patient spinal cord, these cells become astrocytes, the support cells that keep nerve cells functioning. Due to the genetic modifications, the cells also deliver high doses of a growth factor which has been shown to protect nerve cells. The goal of this early stage trial is to test the safety of this astrocyte replacement strategy in ALS patients.


Dose escalation. Open label.


Safety. Dosing. Efficacy - Lower limb strength

News about this clinical trial:

Contact Trial Sponsor

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website